Kite, a Gilead company, has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp's SEGRO Park Amsterdam Airport will enable Kite to manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.
The facility will engineer and produce cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T-cell (CAR-T) therapy that is currently under review by the European Medicines Agency and which is approved in the U.S. as Yescarta.
In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a 26,000 square-foot facility in Gaithersburg, Maryland. The Maryland site will support the work of a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop adoptive cell therapies targeting patient-specific tumor neoantigens.
Read the full Gilead release